What is FP7?

The Framework Programme (FP) is the European Union's main instrument for funding research and development. The FP is proposed by the European Commission and adopted by Council and the European Parliament following a co-decision procedure. FPs have been implemented since 1984 and cover a period of five years with the last year of one FP and the first year of the following FP overlapping. The current FP is FP6, which will be running up to the end of 2006.

It has been proposed for FP7, however, to run for seven years. It will be fully operational as of 1 January 2007 and will expire in 2013. It is designed to build on the achievements of its predecessor towards the creation of the European Research Area, and carry it further towards the development of the knowledge economy and society in Europe.

In the Commission's proposals for the Seventh Framework Programme to the European Parliament and the Council of 6 April 2005, the Commission proposed that the maximum overall amount for Community financial participation in the EC Seventh Framework Programme should be EUR 72 726 million for the period 2007 - 2013. For nuclear research and training activities carried out under the Euratom treaty EUR 3092 million are foreseen for 2007-2011.

On the basis of the first results of the debate on the present proposals, the Commission presented proposals for the Specific Programmes and for the "Rules for Participation" in the Framework Programme to the Council and the European Parliament in the second half of 2005. The key milestones towards FP7 are explained in the FP7 roadmap section.

For further information, please visit:
European Commission FP7 Home

Most Popular Now

Herefordshire and Worcestershire Health …

Herefordshire and Worcestershire Health and Care NHS Trust has successfully implemented Alcidion's Miya Precision platform to streamline bed management workflow across seven community hospitals in Worcestershire. The trust delivers community...

A Shortcut for Drug Discovery

For most human proteins, there are no small molecules known to bind them chemically (so called "ligands"). Ligands frequently represent important starting points for drug development but this knowledge gap...

New Horizon Europe Funding Boosts Europe…

The European Commission has announced the launch of new Horizon Europe calls, with a substantial funding pool of over €112 million. These calls are aimed primarily at pioneering projects in...

Cleveland Clinic Study Finds AI can Deve…

Cleveland Clinic researchers developed an artficial intelligence (AI) model that can determine the best combination and timeline to use when prescribing drugs to treat a bacterial infection, based solely on...

New AI-Technology Estimates Brain Age Us…

As people age, their brains do, too. But if a brain ages prematurely, there is potential for age-related diseases such as mild-cognitive impairment, dementia, or Parkinson's disease. If "brain age...

With Huge Patient Dataset, AI Accurately…

Scientists have designed a new artificial intelligence (AI) model that emulates randomized clinical trials at determining the treatment options most effective at preventing stroke in people with heart disease. The model...

Radboud University Medical Center and Ph…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Radboud University Medical Center have signed a hospital-wide, long-term strategic partnership that delivers the latest patient monitoring...

GPT-4, Google Gemini Fall Short in Breas…

Use of publicly available large language models (LLMs) resulted in changes in breast imaging reports classification that could have a negative effect on patient management, according to a new international...

ChatGPT fails at heart risk assessment

Despite ChatGPT's reported ability to pass medical exams, new research indicates it would be unwise to rely on it for some health assessments, such as whether a patient with chest...

Study Shows ChatGPT Failed when Challeng…

With artificial intelligence (AI) poised to become a fundamental part of clinical research and decision making, many still question the accuracy of ChatGPT, a sophisticated AI language model, to support...

Virtual Reality Shows Promise in Fightin…

A new study published in JMIR Mental Health sheds light on the promising role of virtual reality (VR) in treating major depressive disorder (MDD). Titled "Examining the Efficacy of Extended...

AXREM and Highland Marketing Partner to …

AXREM represents member companies that collectively provide UK hospitals with most of their diagnostic medical imaging technology, and radiotherapy equipment. The association has seen substantial growth in recent years, with membership...